Kangpu Biopharmaceuticals, a clinical-stage company, has successfully concluded a bridging clinical study of KPG-818 in China. This study evaluated the safety, tolerability, and pharmacokinetics of KPG-818 in healthy volunteers, paving the way for future clinical trials in patients.